ESMO 2023 | Residual tumor treatment in mutant BRCA-1 triple-negative breast cancer

Federica Giugliano, MD, Gustave Roussy Cancer Center, Villejuif, France, outlines the treatment of a post-menopausal woman who experienced a residual tumor after undergoing triple-negative breast cancer treatment under the KEYNOTE 522 trial’s (NCT03036488) guidelines: carboplatine-based chemotherapy and pembrolizumab. Following a mastectomy, a small residual tumor remained; the patient was treated with olaparib rather than further pembrolizumab due to a germline BRCA-1 mutation. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.